BARDA

GAITHERSBURG, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a 10-year contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the…

-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement expected in early 2024 BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc.…

WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Sabin a multi-year contract with funding potential for up to…

WASHINGTON, 12 janv. 2023 (GLOBE NEWSWIRE) -- Le Sabin Vaccine Institute a annoncé aujourd'hui que la Biomedical Advanced Research and Development Authority (BARDA) avait attribué à Sabin un contrat pluriannuel avec un potentiel de…

WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) -- O Sabin Vaccine Institute anunciou hoje que a Biomedical Advanced Research and Development Authority (BARDA) fechou com a Sabin um contrato plurianual com potencial de financiamento de até US…

WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) -- El Sabin Vaccine Institute anunció hoy que la Autoridad de Investigación y Desarrollo Avanzado Biomédico (BARDA) concedió a Sabin un contrato de varios años con un potencial de financiamiento…

Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022Procurement Triggered by Positive Top-Line Data from Pilot Efficacy Study of NUZYRA for the Treatment of Pulmonary Anthrax Announced in December…

– First award from the agency’s solicitation for contracts for Pre-Exposure Prophylaxis for Influenza – – Initial investment of approximately $55 million from Biomedical Advanced Research and Development Authority to support development…

-- ENA-001, a new chemical entity with a unique mechanism of action, is being developed as an agnostic respiratory stimulant for use in multiple patient populations experiencing acute respiratory depression -- -- Development is under way…

- Initial Procurement of 319,000 Treatment Courses for $115M with Additional Procurements at BARDA’s Discretion Over 10 Years – - Emergent BioSolutions, Inc. Payment Increases to $238M Upfront and $136.5M in Potential Milestones -…